ValiRx PLC - Essex, England-based life science company focused on early-stage cancer therapeutics and women’s health - Says subsidiary Inaphea BioLabs Ltd will partner with an unnamed UK-based biotechnology company on a phenotypic assay to investigate anti-cancer properties using patient-derived cells from Inaphea’s biobank. Adds Inaphea has started internal studies on ValiRx assets s VAL301 and Cytolytix CLX001. ‘This defined work programme involves a multi-stage project and is expected to complete at the end of September 2023,’ ValiRx says.

Chief Executive Officer Suzy Dilly says: ‘We are looking forward to working closely with this client, and hope for this to be the first contract in a substantial working relationship. With the first revenues now being generated by Inaphaea, we are delighted that our service offering is being well received and welcomed by our intended client base.’

Current stock price: 7.40 pence, up 9.6% on Wednesday

12-month change: down 33%

Copyright 2023 Alliance News Ltd. All Rights Reserved.